Hypertension is a multigene and multifactorial disorder affecting -25% of the population. To demonstrate potential therapeutic effects of human tissue kallikrein in hypertension, spontaneously hypertensive rats were subjected to somatic gene therapy. Two human tissue kallikrein DNA constructs, one under the promoter control of the metallothionein metal response element and the other under the control of the Rous sarcoma virus 3'-LTR, were generated. We delivered naked DNA constructs into spontaneously hypertensive rats via intravenous injection. The expression of human tissue kallikrein in rats was identified in the heart, lung, and kidney by reverse transcription polymerase chain reaction followed by Southern blot analysis and an ELISA specific for human tissue kallikrein. A single injection of both human kallikrein plasmid DNA constructs caused a sustained reduction of blood pressure which began 1 wk after injection and continued for 6 wk. A maximal effect of blood pressure reduction of 46 mmHg in rats was observed 2-3 wk after injection with kallikrein DNA as compared to rats with vector DNA (n = 6, P < 0.05). 
Introduction
Tissue kallikreins (E.C. 3.4.21.35) belong to a subgroup of serine proteinases which are involved in the posttranslational processing of peptide precursors to their bioactive forms. One of the main biological functions of tissue kallikrein is to process October 1994. kininogen substrates and release vasoactive kinin peptides ( 1, 2) . Kinins have a broad spectrum of biological effects including vasodilation, smooth muscle contraction and relaxation, pain, inflammation, increase in ion and glucose transport, and reduction of blood pressure. The fact that kinin has a low concentration in plasma and a short half-life in the circulation suggests that kinin acts as a local hormone.
The tissue kallikrein-kinin system has been implicated in the pathogenesis of hypertension (3, 4) . Essential hypertension appears to be a polygenic disease and several genes are likely involved in the genetic determination of blood pressure. The observation that urinary excretion of tissue kallikrein was significantly reduced in hypertensive individuals was reported in 1934 and confirmed more than three decades later (5, 6) . Epidemiological studies showed that urinary kallikrein levels are inversely correlated with blood pressure in infants, children, and parents (7, 8) . A study involving Utah pedigrees indicates that a dominant allele expressed as high urinary kallikrein excretion may be associated with a decreased risk of essential hypertension (9) . Reduced urinary kallikrein excretion has also been described in a number of genetically hypertensive rats (10) (11) (12) (13) . In addition, rat tissue kallikrein has been linked with blood pressure regulation by restriction fragment length polymorphism and cosegregation studies in genetically hypertensive rats ( 14, 15 ) . These findings suggest that low renal kallikrein levels may contribute to hypertension and high urinary kallikrein could have a protective effect against hypertension. Clinical studies have shown that the blood pressure of hypertensive patients can be temporarily lowered by oral administration of pig pancreatic kallikrein ( 16, 17) . However, to achieve this hypotensive effect, a large quantity and repeated administration of purified tissue kallikrein are required.
To establish the role of the kallikrein-kinin system in blood pressure control, we developed transgenic mouse lines that express the human tissue kallikrein gene under the control of the metal response element (MRE)' promoter of the metallothionein gene (18) . We 40) , and included a Kozak translation initiation sequence (CCACCATGG) immediately 5' to the translation initiation codon (20) . The plasmid metal response element (MRE-pHK), the human tissue kallikrein gene under the control of the MRE of the mouse metallothionein gene (21) , was constructed as previously described (18) . Transient were randomly divided into three groups with six animals in each. Three plasmid DNA constructs, pREP8, RSV-cHK, and MRE-pHK, were diluted to 500 ;ig/ml in PBS containing 5% glucose and were injected into the tail vein of SHR at a dose of 500 jig/rat. Blood pressure measurement. Systolic blood pressure of SHR was measured with a programmed electro-sphygmomanometer (PE-300; Narco Bio-Systems, Inc., Austin, TX) using the tail-cuff method (18) . Unanesthetized rats were placed in a plastic holder mounted on a thermostatically controlled warm plate that was maintained at 370C during measurement. An average of six readings were taken for each animal.
Aprotinin administration. Six SHR injected with MRE-pHK plasmid DNA were randomly divided into two groups 6 wk after plasmid DNA delivery. In the control group, three SHR were subcutaneously injected with 0.5 ml of PBS and in the aprotinin group, three SHR were subcutaneously injected with 5 mg of aprotinin in 0.5 ml of PBS. The effect of aprotinin on the blood pressure of SHR injected with MRE-pHK plasmid DNA was evaluated at 1 and 3 d after aprotinin administration.
ELISA specific for human tissue kallikrein. Rats treated with kallikrein DNA or vector DNA were anesthetized with pentobarbital and perfused with saline (0.85% NaCl). Tissues were immersed in PBS (pH 7.0), and homogenized immediately with a Polytron (Brinkman Instruments, Westbury, NY). The homogenate was centrifuged at 600 g for 10 min. The supernatant was incubated in 0.5% sodium deoxycholate and then centrifuged at 10,000 g for 30 min. Total protein was determined by Lowry's method (27) . The level of human tissue kallikrein in each tissue extract was determined by ELISA specific for human tissue kallikrein using methods similar to previously described procedures (28) . Anti-human tissue kallikrein IgG was coupled to biotin (29) . Microtiter plates (96 well) were coated with antikallikrein IgG (2 Hg/ml, 100 kul/well) overnight at 4TC. Purified kallikrein standard (0.04-2.5 ng) and rat tissue extracts were added to individual wells in a total vol of 100 ,ul of PBS containing 0.05% Tween-20 and 0.5% gelatin (dilution buffer). Biotin-labeled anti-human tissue kallikrein IgG was added in each well at a concentration of 1 jg/ml in a total of 100 ,sl. Peroxidase-avidin (1 jg/ml in a total of 100 ,u) was added and incubated at 37°C for 60 min. The color reaction was performed by adding 100 jl/well of freshly prepared substrate solution [0.03% 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) and 0.03% H202 in 0.1 M citrate buffer, pH 4.3] and incubating at room temperature for 30 min. The plates were read at 414 nm with a Titertek plate reader (Elfab Oy, Finland).
Assays for serum antibodies in rats. Immunological responses were monitored by measuring production of antibodies against human tissue kallikrein or kallikrein plasmid DNA (MRE-pHK) in the sera of experimental rats. Serum antibodies binding to human tissue kallikrein protein or kallikrein DNA were measured by ELISA (28) . Microtiter ELISA plates were coated with either purified human tissue kallikrein at 5 jig/ ml in PBS at 4°C or with purified kallikrein DNA construct at 5 jsg/ml in SSC (150 mM sodium chloride, 15 mM sodium citrate, pH 7.0) at 37°C overnight (30) . Serially diluted rat sera in PBS containing 0.05% Tween 20 were added to the plates. After incubation for 45 min at room temperature, plates were washed and peroxidase-conjugated goat antirat IgG was added. Substrate solution was added and the plates were read at 414 nm on a Titertek plate reader.
RT-PCR Southern blot analysis of human tissue kallikrein mRNA. Total RNA was extracted from fresh rat tissues or human colonic carcinoma T84 cells by guanidine isothiocyanate-CsCl gradient centrifugation (31) . The reaction mixture for RT contained 1 Hg of total RNA from human colonic carcinoma T84 cell or 4 Hg of total RNA from SHR, 20 Hypotensive effect of gene delivery of human tissue kallikrein to SHR. The effect of administering two human tissue kallikrein DNA constructs, RSV-cHK and MRE-pHK on the blood pressure of SHR was determined 1-6 wk after intravenous injection. The plasmid vector pREP8 DNA was injected intravenously as a control. The results show that the kallikrein constructs produced a significant reduction in systolic blood pressure (Fig. 4) . The basal blood pressure was 170-190 mmHg in all experimental groups before gene delivery. Systolic blood pressure in SHR injected with the vector pREP8 plasmid DNA increased 28 and 22 mmHg at 1 and 2 wk after injection, respectively. Increases in systolic blood pressure of 20 mmHg at 1 and 2 wk after intravenous injection were occasionally observed. The systolic blood pressures of SHR injected with RSV-cHK (184±7 mmHg, n = 6) and MRE-pHK (186+4 mmHg, n = 6) were significantly decreased (P < 0.05), compared with SHR injected with pREP8 vector DNA (203±5 mmHg, n = 6) 1 wk after injection. The reduction of systolic blood pressure was sustained for 6 wk. The differences in systolic blood pressure of SHR administered with vector DNA and two kallikrein DNA constructs, RSV-cHK and MRE-pHK, reached a maximum of 32 and 46 mmHg, respectively at 2 wk after intravenous injection. Compared with the vector plasmid DNA, both human tissue kallikrein DNA constructs, RSV-cHK and MRE-pHK significantly decreased systolic blood pressure (P < 0.05) from 1 to 6 wk after injection. At 7 wk after injection, there was no significant difference in systolic blood pressure of SHR receiving injections of pREP8 (181±2 mmHg, n = 6) and RSV-cHK (176±8 mmHg, n = 6), or MRE-pHK (174±9 mmHg, n = 6) plasmid DNA. In recent years, evidence has been gathered to support the existence of a vascular kallikrein-kinin system in the rat and human. A kininogenase resembling glandular kallikrein is present in rat arteries and veins (33). Local synthesis of kallikrein is supported by the presence of specific kallikrein messenger RNA in rat vasculature (34) . The arterial vasodilating action of kinins is mediated by the release of endothelium-derived relaxing factors and prostacyclin from endothelial cells. Kininogenase activity in thoracic aorta of SHR was lower than in agematched Wistar-Kyoto rats (35). It was hypothesized that the defective kinin release may contribute to increased blood pressure in SHR (35). An increased level of kinin generated by exogenous tissue kallikrein locally or in the circulation could be an alternative way to regulate blood pressure. In human arterial and venous vessels, a glandular kallikrein-like enzyme is present in both active and latent forms (36) . Total amidolytic activity toward a peptidyl chromogenic substrate, Val-Leu-Argp-nitroanilide, was found in saphenous vein homogenates and the activity was inversely correlated with mean blood pressure (37). In this study, exogenous human tissue kallikrein was detected in the heart of SHR suggesting that heart and arteries and veins are the primary targets that mediate the physiological function of exogenous kallikrein, which ultimately leads to a decrease in blood pressure.
It has been reported that intravenous injection of bradykinin or kallikrein causes a brief fall in blood pressure (38) . Oral administration of pig pancreatic kallikrein has been shown to cause a temporary lowering of blood pressure in hypertensive patients ( 16, 17) . Recently, oral kallikrein therapy on salt-sensitive essential hypertensive patients has been reported (39 (40) .
Our present studies show that a single injection of the human tissue kallikrein gene results in expression of its encoded kallikrein and causes a reduction of blood pressure in SHR up to 6 wk. Prolonged expression of unprotected DNA was first demonstrated in mice after intramuscular injection (41) . Gene delivery by intravenous injection has been demonstrated with the reporter gene construct. A single intravenous injection of the CAT expression plasmid complexed with cationic liposome into adult mice produced generalized CAT gene expression for at least 9 wk. High levels of CAT activity were present in the lung, spleen, liver, heart, kidney, and lymph nodes (42) . We demonstrated r k I that somatic gene delivery by intravenous injection of unprotected human tissue kallikrein plasmid DNA results in low, but generalized expression of human tissue kallikrein in heart, kidney, and lung and induces a significant reduction of blood pressure in the hypertensive rat model.
Previous studies showed that blood pressures of normotensive rats were not changed after either acute or chronic administration of aprotinin (43, 44) . At 3 d after subcutaneous injection of aprotinin, renal and urinary kallikrein-like activities were markedly reduced (44) . In addition, it has also been shown that a single subcutaneous injection of aprotinin, a potent tissue kallikrein inhibitor, resulted in accumulation of aprotinin in renal proximal tubule cells of rats for at least 3 d (32). We used the same gene delivery protocol as described in Methods to normotensive Sprague Dawley rats and found that the blood pressures were not affected up to 4 wk except for a slight blood pressure increase at 1 wk after injection (data not shown). The initial increase of blood pressure observed in Sprague Dawley rats was similar to that observed in SHR. We have repeated the experiments a number of times and often observed this phenomenon. We speculate that the injection procedure induces a psychological stress which causes a transient increase of blood pressure in rats receiving either vector DNA or DNA constructs harboring the human tissue kallikrein gene. To alleviate the possibility of any blood pressure increase caused by the gene delivery procedure, alternative delivery methods will be pursued.
The development of efficient gene transfer methods in hypertensive animal models is essential to establishing practical therapeutic regimens in treating hypertensive diseases. Although viral vectors that have high levels of expression have been used for in vitro gene transfer experiments and human trials (45) , their potential hazard is a concern since viral vectors used for gene delivery may have an opportunity for chromosomal insertion and therefore cause chromosomal breakage or carcinogenesis. Direct gene delivery by naked DNA, liposome, and receptor-mediated endocytosis have demonstrated expression of foreign products, and these methods may avoid potential hazards of using recombinant viruses in patients. By comparing different delivery methods in hypertensive animal models, it is possible to identify the best means of direct delivery of the human tissue kallikrein gene with combined advantages of high efficiency and safety.
Hypertension is the leading cause of both morbidity and mortality in the United States. Conventional therapy requires daily drug intake to control high blood pressure. The major advantage of applying kallikrein gene therapy is that a single injection of a gene construct has a long-lasting effect for months without apparent side effects. A potential problem with this technology may be the development of an immune response to the gene product after repeated injections. We found that the animals did not develop antibodies to either human tissue kallikrein or kallikrein DNA up to 7 wk after injection of the gene construct. In addition, rats receiving kallikrein gene delivery did not experience any weight loss or changes in activity. Therefore, somatic gene therapy using human tissue kallikrein constructs offers a noninvasive, and a potentially important clinical alternative for treating human hypertensive diseases.
